1. Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort. (14th October 2021) Authors: Blaum, C; Brunner, F J; Kroeger, F; Bay, B; Gossling, A; Lorenz, T; Graef, A; Zeller, T; Schnabel, R; Clemmensen, P; Westermann, D; Blankenberg, S; Seiffert, M; Waldeyer, C Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort. (25th November 2020) Authors: Blaum, C; Brunner, F.J; Kroeger, F; Braetz, J; Bay, B; Graef, A; Gossling, A; Lorenz, T; Zeller, T; Karakas, M; Schnabel, R.B; Westermann, D; Blankenberg, S; Seiffert, M; Waldeyer, C Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗